EuBiologics

Focus: EuBiologics is a Korean biotechnology company focused on vaccine development across infectious diseases including COVID-19, cholera, typhoid, meningococcal, and RSV. The company operates as a mid-stage vaccine specialist with a geographically concentrated research footprint.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About EuBiologics

AI assessmentNot Hiring

No open roles listed right now. Follow EuBiologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EuPCV15

Pneumococcal Disease

Phase 1

Clinical Trials (1)

NCT04830358Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

Phase 1

Help build intelligence for EuBiologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified Phase 3 pipeline with 7 late-stage programs offering multiple near-term catalysts across high-burden infectious diseases
Specialized vaccine expertise in underserved markets (cholera, typhoid) with global health relevance and emerging markets opportunity
Early-stage COVID-19 vaccine program (EuCorVac-19) with Phase 1/2 and Phase 3 trials active, positioning for pandemic preparedness market

Watch Out For

No active job openings listed and incomplete staffing data limit visibility into hiring momentum and team stability
Absence of published financial data, revenue information, or funding history makes assessment of runway, profitability, and capital structure impossible
Sparse public profile—no patent cliff analysis, FDA warnings, or recent news available suggests limited market presence or disclosure

Generated by Claude from EuBiologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Euvichol

Prevention Harmful Effects

Phase 1

Clinical Trials (1)

NCT01707537To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Phase 1

EuRSV

Respiratory Syncytial Virus Infections

Phase 1

Clinical Trials (1)

NCT06216093Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

Phase 1